Abstract
2/2022
vol. 14
Case report
High-dose-rate interstitial brachytherapy as a suitable option for metastatic extraskeletal myxoid chondrosarcoma – a case report
- Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Department of Medical Physics, National Cancer Center Hospital, Tokyo, Japan
- Department of Radiation Therapy Center, Shin-Matsudo Central General Hospital, Chiba, Japan
J Contemp Brachytherapy 2022; 14, 2: 198–204
Online publish date: 2022/03/31
We report on a patient with metastatic extraskeletal myxoid chondrosarcoma (EMC), who was treated with palliative high-dose-rate (HDR) interstitial brachytherapy (ISBT). The patient was an 87-year-old woman who underwent an amputation for a bulky tumor in her right ankle joint. EMC was histopathologically confirmed. She presented with a large right inguinal lymph node metastasis of EMC 16 months after surgery. Palliative HDR-ISBT (30 Gy/2 fractions in 1 day) for the right inguinal lymph node metastasis was administered to shorten treatment period. Additional HDR-ISBT (30 Gy/2 fractions in 1 day) was administered for the management of subsequent subcutaneous metastasis to the right breast and right popliteal fossa. HDR-ISBT provided significant long-term control of the recurrent tumor in all three sites, without severe acute and late toxicity. Thus, HDR-ISBT regimen of 30 Gy/2 fractions in 1 day can be a suitable option for both palliation and long-term local control for patients with metastatic EMC.
Keywords
extraskeletal myxoid chondrosarcoma, palliation, high-dose-rate, interstitial brachytherapy
Indexed in
Integrated with
Editorial Policies
